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Background:  Chemotherapeutic agents doxorubicin and trastuzumab are being used for various tumors but efficacy is often limited by related 
cardiotoxicity, leaings to cardiomyopathy and heart failure. Despite routine tracking of ejection fractions (by echocardiography or MUGA (Multigated 
Acquisition) scan) some patients still develop severe left ventricular dysfunction. Recent data suggest that Troponin-I and B-type natriuretic peptide 
(BNP) may serve as cardiac biomarkers for early detection of cardiotoxicity. This study seeks to evaluate utility of these markers in clinical setting. 
Methods:  A retrospective chart review of 75 patients who received doxorubicin and/ or trastuzumab was done with prior IRB approval. Each 
patient had serum Troponin-I and BNP measured prior to each dose of doxorubicin, and every three months on trastuzumab. Cardiac function was 
measured either by MUGA scan or Echo before and after chemotherapy and patients were followed up for median of 24 months. 
Results:  Of the 75 patients, 11 (15.7%) patients had abnormal LVEF(ejection fraction) by MUGA scan/ echo following chemotherapy. Nine (81%) 
of these patients had rise in Troponin-I/BNP. Negative predictive value of these biomarkers was 92.3%, with sensitivity of 81% and specificity of 
40.6%. 
Conclusion: Use of cardiac biomarkers (Troponin I and BNP) can identify doxorubicin and trastuzumab treated patients who are at risk of 
cardiotoxicity and their elevation indicates worse prognosis for recovery of cardiac function. 
Median Age 51 ( 30 - 75 ) yrs
No of patients treated with dose dense doxorubicin 66 (88%)
No of patients treated with Trastuzumab 25 ( 33%)
Median follow up 24 months
Troponin rise during chemotherapy 40 ( 57%)
BNP rise during chemotherapy 18 (25%)
Cardiac risk factors 35 (50%) 
Coronary Interventions 13 (18%)
Abnormal follow up MUGA scan 11( 15.7%)
Abnormal follow up MUGA scan with elevated TroponinI and/ BNP 9 (81%)
Patients with LVEF recovery on repeat MUGA 6/11 ( 54.6%)
Patient with LVEF recovery with previous normal Troponin I and BNP 2/2 ( 100%)
Patient with LVEF recovery with previous abnormal Troponin I and BNP 1/4( 25%)
